MedPath

Trevena, Inc.

Trevena, Inc. logo
🇺🇸United States
Ownership
Public
Established
2007-01-01
Employees
23
Market Cap
$3.9M
Website
http://www.trevena.com

Clinical Trials

28

Active:9
Completed:17

Trial Phases

3 Phases

Phase 1:19
Phase 2:4
Phase 3:3

Drug Approvals

1

FDA:1

Drug Approvals

OLINVYK

Approval Date
Dec 20, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials

Phase 1
19 (73.1%)
Phase 2
4 (15.4%)
Phase 3
3 (11.5%)

A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250

Phase 1
Terminated
Conditions
Migraines
Interventions
Drug: Placebo
First Posted Date
2019-12-17
Last Posted Date
2021-09-22
Lead Sponsor
Trevena Inc.
Target Recruit Count
9
Registration Number
NCT04201080
Locations
🇬🇧

MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence, Manchester, Greater Mancherster, United Kingdom

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

Phase 3
Completed
Conditions
Acute Pain
Interventions
First Posted Date
2016-06-30
Last Posted Date
2020-10-23
Lead Sponsor
Trevena Inc.
Target Recruit Count
407
Registration Number
NCT02820324
Locations
🇺🇸

Research Site, San Antonio, Texas, United States

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy

Phase 3
Completed
Conditions
Acute Pain
Interventions
First Posted Date
2016-06-28
Last Posted Date
2020-09-25
Lead Sponsor
Trevena Inc.
Target Recruit Count
418
Registration Number
NCT02815709
Locations
🇺🇸

Research Site, San Antonio, Texas, United States

🇺🇸

Resarch Site, Salt Lake City, Utah, United States

A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain

Phase 3
Completed
Conditions
Acute Pain
Interventions
First Posted Date
2016-01-15
Last Posted Date
2020-09-24
Lead Sponsor
Trevena Inc.
Target Recruit Count
768
Registration Number
NCT02656875
Locations
🇺🇸

Recruiting, Murray, Utah, United States

A Pilot Study of TRV130 for the Treatment of Fracture Pain

Phase 2
Terminated
Conditions
Pain
Interventions
First Posted Date
2015-08-11
Last Posted Date
2020-09-07
Lead Sponsor
Trevena Inc.
Target Recruit Count
1
Registration Number
NCT02520297
Locations
🇺🇸

Trevena, Inc., Indianapolis, Indiana, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath